- Article metrics
- Last updated: Wed, 8 Oct 2025 23:20:15 Z
Dual-vector rAAVrh8 gene therapy for GM2 gangliosidosis: a phase 1/2 trial
Access & Citations
-
- 8728
- Article Accesses
-
- 1
- Citation
Citation counts are provided by Dimensions and depend on their data availability. Counts will update daily, once available.
Online attention
- 26 tweeters
- 3 blogs
- 1 Facebook pages
- 16 news outlets
- 9 Mendeley
This article is in the 99th percentile (ranked 3,437th) of the 324,528 tracked articles of a similar age in all journals and the 80th percentile (ranked 35th) of the 178 tracked articles of a similar age in Nature Medicine
View more on Altmetric
Altmetric calculates a score based on the online attention an article receives. Each coloured thread in the circle represents a different type of online attention. The number in the centre is the Altmetric score. Social media and mainstream news media are the main sources that calculate the score. Reference managers such as Mendeley are also tracked but do not contribute to the score. Older articles often score higher because they have had more time to get noticed. To account for this, Altmetric has included the context data for other articles of a similar age.
Mentions in news and blogs
-
The First Sparks of Healing Emerge in a Battle Once Thought Impossible
Science News Today -
Dual-Vector rAAVrh8 Gene Therapy for GM2 Gangliosidosis: A Phase I/II Trial
Stemcell science news -
HMN 2025: How Dual vector gene therapy trial offers hope for Tay-Sachs and Sandhoff diseases
Health Medicine Network
This list highlights individual mainstream news articles and blogs that cite the article. Not all news and blogs link to articles in a way that Altmetric can pick up, so they are not representative of all media. Altmetric are responsible for the curation of this list and provide updates hourly.